4.8 Article

Dual Affinity to RBCs and Target Cells (DART) Enhances Both Organ- and Cell Type-Targeting of Intravascular Nanocarriers

期刊

ACS NANO
卷 16, 期 3, 页码 4666-4683

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsnano.1c11374

关键词

nanocarriers; RBC hitchhiking; liposomes; dual targeting; click chemistry; vascular targeting; human lung delivery

资金

  1. NIH [HL157189, HL143806, H138269, HL153510, HL13522, 5T32HL007586-34]
  2. National Center for Advancing Translational Sciences of the National Institutes of Health [TL1TR001880]

向作者/读者索取更多资源

The goal of nanomedicine is to improve drug effectiveness by using nanocarriers that specifically target certain cells and organs. However, current technologies often result in only a small percentage of the drug reaching the target organ, and cell-specific targeting is rarely achieved. To address these issues, DART introduces nanocarriers that have dual affinity to red blood cells and target cells, allowing for better accumulation in the target organ and specific delivery to target cells.
A long-standing goal of nanomedicine is to improve a drug's benefit by loading it into a nanocarrier that homes solely to a specific target cell and organ. Unfortunately, nanocarriers usually end up with only a small percentage of the injected dose (% ID) in the target organ, due largely to clearance by the liver and spleen. Further, cell-type-specific targeting is rarely achieved without reducing target organ accumulation. To solve these problems, we introduce DART (dual affinity to RBCs and target cells), in which nanocarriers are conjugated to two affinity ligands, one binding red blood cells and one binding a target cell (here, pulmonary endothelial cells). DART nanocarriers first bind red blood cells and then transfer to the target organ's endothelial cells as the bound red blood cells squeeze through capillaries. We show that within minutes after intravascular injection in mice nearly 70% ID of DART nanocarriers accumulate in the target organ (lungs), more than doubling the % ID ceiling achieved by a multitude of prior technologies, finally achieving a majority % ID in a target organ. Humanized DART nanocarriers in ex vivo perfused human lungs recapitulate this phenomenon. Furthermore, DART enhances the selectivity of delivery to target endothelial cells over local phagocytes within the target organ by 6-fold. DART's marked improvement in both organ- and cell-type targeting may thus be helpful in localizing drugs for a multitude of medical applications.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据